Alkaline-cell lysis through in-line static mixer reactor for the production of plasmid DNA for gene therapy

2006 ◽  
Vol 96 (3) ◽  
pp. 471-482 ◽  
Author(s):  
Saethawat Chamsart ◽  
Tanyawat Karnjanasorn
Keyword(s):  
Gene Therapy ◽  
Plasmid Dna ◽  
Cell Lysis ◽  
Static Mixer ◽  
Alkaline Cell

The impact of fluid-dynamic-generated stresses on chDNA and pDNA stability during alkaline cell lysis for gene therapy products

2001 ◽  
Vol 75 (4) ◽  
pp. 387-392 ◽  
Author(s):  
S. Chamsart ◽  
H. Patel ◽  
J. A. J. Hanak ◽  
A. G. Hitchcock ◽  
A. W. Nienow
Keyword(s):  
Gene Therapy ◽  
Fluid Dynamic ◽  
Cell Lysis ◽  
Alkaline Cell ◽  
The Impact

Arf6-mediated macropinocytosis enhanced suicide gene therapy of C16TAB-condensed Tat/pDNA nanoparticles in ovarian cancer

Nanoscale ◽  
2021 ◽  
Author(s):  
Zhe Sun ◽  
Jinhai Huang ◽  
Linjia Su ◽  
Jing Li ◽  
Fangzheng Qi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Gene Therapy ◽  
Cancer Treatment ◽  
Plasmid Dna ◽  
Suicide Gene ◽  
Cell Penetrating Peptides ◽  
Therapeutic Gene ◽  
Hiv Tat ◽  
Efficient Delivery ◽  
Cell Penetrating

Using cell-penetrating peptides (CPPs), typically HIV-Tat, to deliver the therapeutic gene for cancer treatment has being hampered by low efficient delivery and complicated uptake route of plasmid DNA (pDNA). On...

Evaluation of Plasmid DNA for in Vivo Gene Therapy: Factors Affecting the Number of Transfected Fibers

1998 ◽  
Vol 87 (6) ◽  
pp. 763-768 ◽  
Author(s):  
Dominic J. Wells ◽  
Jake Maule ◽  
Jill McMahon ◽  
Roger Mitchell ◽  
Elsie Damien ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Plasmid Dna ◽  
Factors Affecting

scholarly journals Improved downstream process for the production of plasmid DNA for gene therapy.

2005 ◽  
Vol 52 (3) ◽  
pp. 703-711 ◽  
Author(s):  
Jochen Urthaler ◽  
Wolfgang Buchinger ◽  
Roman Necina
Keyword(s):  
Gene Therapy ◽  
Plasmid Dna ◽  
Viral Vectors ◽  
Continuous System ◽  
Size Exclusion ◽  
High Yield ◽  
Downstream Process ◽  
Naked Dna ◽  
Supercoiled Form ◽  
Exclusion Chromatography

Gene therapy and genetic vaccines promise to revolutionize the treatment of inherited and acquired diseases. Since viral vectors are generally associated with numerous disadvantages when applied to humans, the administration of naked DNA, or DNA packed into lipo- or polyplexes emerge as viable alternatives. To satisfy the increasing demand for pharmaceutical grade plasmids we developed a novel economic downstream process which overcomes the bottlenecks of common lab-scale techniques and meets all regulatory requirements. After cell lysis by an in-house developed gentle, automated continuous system the sequence of hydrophobic interaction, anion exchange and size exclusion chromatography guarantees the separation of impurities as well as undesired plasmid isoforms. After the consecutive chromatography steps, adjustment of concentration and final filtration are carried out. The final process was proven to be generally applicable and can be used from early clinical phases to market-supply. It is scaleable and free of animal-derived substances, detergents (except lysis) and organic solvents. The process delivers high-purity plasmid DNA of homogeneities up to 98% supercoiled form at a high yield in any desired final buffer.

scholarly journals Osteogenic differentiation as a result of BMP-2 plasmid DNA based gene therapy in vitro and in vivo

2011 ◽  
Vol 21 ◽  
pp. 230-242 ◽  
Author(s):  
F Wegman ◽  
◽  
A Bijenhof ◽  
L Schuijff ◽  
FC Öner ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Osteogenic Differentiation ◽  
Plasmid Dna
Sign in / Sign up

Export Citation Format

Share Document